Jump to navigation

  • IHME
  • GHDx
  • GBD Compare
Home
Main menu
  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
      • IHME Foundations
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Online Training
    • Workshops
  • About
    • Our Principles
    • Racism is a public health issue.
    • Senior Management Team
    • Faculty
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Explore section

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Acne vulgaris — Level 3 cause


Summary Globally, acne vulgaris was responsible for 4·96 million (95% UI 2·98–7·85) DALYs in 2019. Of these, 3·52 million (2·11–5·64) DALYs occurred in those ages 15–49 years old.

Definition Acne vulgaris (or acne) is a chronic inflammatory disease of the pilosebaceous unit associated with an increase in sebum secretion (ICD-10: L70, excluding L70.4).

Total sources
Incidence 0
Prevalence 90
Remission 0
Causes of death 0
Other 15
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •Instead of DisMod-MR, MR-BRT was used to adjust outpatient data (and data that were not based on physical exams) toward the level of other prevalence datapoints, which were more representative of the general population.
  • •Data for both sexes combined and large age categories were assigned to sex-specific and more fine-grained age categories.
  • •New data from Poland (2015–2017) and USA claims data (2015–2016) were incorporated into the model.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
231
(208
to 255)
3073·3
(2761·6
to 3403·1)
117
(103
to 134)
1585·9
(1384·8
to 1812·2)
-–
-–
-–
-–
4·96
(2·98
to 7·85)
65·9
(39·6
to 104·4)
4·96
(2·98
to 7·85)
65·9
(39·6
to 104·4)
Females
129
(116
to 141)
3485·9
(3143·8
to 3846·4)
65·0
(57·2
to 73·7)
1796·0
(1570·8
to 2045·9)
-–
-–
-–
-–
2·75
(1·65
to 4·34)
74·5
(44·8
to 117·9)
2·75
(1·65
to 4·34)
74·5
(44·8
to 117·9)
Males
103
(91·8
to 114)
2675·9
(2392·9
to 2978·7)
52·4
(45·9
to 59·9)
1384·9
(1206·7
to 1586·9)
-–
-–
-–
-–
2·21
(1·32
to 3·51)
57·6
(34·4
to 91·6)
2·21
(1·32
to 3·51)
57·6
(34·4
to 91·6)
Percentage change 2010-19
Both Sexes
8·2%
(7·8
to 8·7)
4·1%
(3·6
to 4·6)
9·8%
(9·0
to 10·6)
4·9%
(4·2
to 5·6)
-–
-–
-–
-–
8·2%
(7·4
to 8·9)
4·1%
(3·3
to 4·8)
8·2%
(7·4
to 8·9)
4·1%
(3·3
to 4·8)
Females
7·5%
(6·9
to 8·1)
3·3%
(2·7
to 3·9)
9·3%
(8·3
to 10·3)
4·3%
(3·5
to 5·2)
-–
-–
-–
-–
7·4%
(6·5
to 8·3)
3·3%
(2·4
to 4·1)
7·4%
(6·5
to 8·3)
3·3%
(2·4
to 4·1)
Males
9·2%
(8·5
to 9·8)
5·2%
(4·4
to 5·8)
10·4%
(9·5
to 11·3)
5·6%
(4·7
to 6·4)
-–
-–
-–
-–
9·1%
(8·1
to 10·2)
5·1%
(4·0
to 6·1)
9·1%
(8·1
to 10·2)
5·1%
(4·0
to 6·1)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 -- -- 42nd 95th
2010 -- -- 37th 87th
2019 -- -- 37th 83rd
Table 3: Rank among Level 3 causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by constituent sequelae YLDs for both sexes combined, 2019
No Legend
Figure 2: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 3: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 4: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Stay connected

     

IHME

Institute for Health Metrics and Evaluation

Population Health Building/Hans Rosling Center

3980 15th Ave. NE, Seattle, WA 98195

UW Campus Box #351615

Tel: +1-206-897-2800

Fax: +1-206-897-2899

© 2020 University of Washington

  • Privacy policy
  • Login

  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Online Training
    • Workshops
  • About
    • Our Principles
    • Racism is a public health issue.
    • Senior Management Team
    • Faculty
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Projects

  • Global Burden of Disease (GBD)
  • Disease Control Priorities Network (DCPN)
  • ABCE+: A Focus on Antiretroviral Therapy (ART)
  • Access, Bottlenecks, Costs, and Equity (ABCE)
  • Efficacy to Effectiveness
  • Viral Load Pilot
  • Salud Mesoamérica Initiative
  • Improving Methods to Measure Comparable Mortality by Cause
  • Verbal Autopsy (VA)
  • Disease Expenditure (DEX)
  • State-level disease burden initiative in India
  • US Counties Drivers of Health Study
  • University of Washington Center for Health Trends and Forecasts